Jump to content

Carey K. Anders

Add links
From Wikipedia, the free encyclopedia
Carey K. Anders
FASCO
Academic background
Alma mater
Academic work
Disciplinemedicine
Sub-disciplineoncology
Institutions
Main interestsbrain metastasis

Carey K. Anders, MD, is a cancer researcher, professor of medicine,[1] and medical oncologist. She currently serves as Director for the Duke Center for Brain and Spine Metastasis (DCBSM) in the School of Medicine at Duke University Health System.[2]

Anders studies the genetic sequencing, prognosis and treatment of brain metastasis and its relationship to primary forms of cancer, in particular breast cancer.[3][4] Patients with brain metastasis have traditionally been excluded from clinical trials.[5][1] Anders' work has led to the development of novel therapies for those with brain metastases,[5][1][6] including triple negative and HER2-positive breast cancer.[7]

Anders is a Fellow of the American Society of Clinical Oncology (FASCO)[8] and an inaugural co-recipient of the Weatherspoon Family Brain Tumor Research Award.[3] In 2021, her work was recognized by the American Society of Clinical Oncology as an important advance in clinical progress against cancer.[9][10]

Early life and education

[edit]

Carey Kernodle Anders[11] is a daughter of Harold B. Kernodle, Jr., an orthopedic surgeon, and his wife Lucy Hendrick Kernodle, a registered nurse. The couple lived in Graham, North Carolina,[12] and worked in Burlington, North Carolina.[13][14][15]

Carey Kernodle received her M.D. from the Brody School of Medicine at East Carolina University in 2002.[16] She then held an Internal Medicine Residency at the Duke University School of Medicine from 2002 to 2005, followed by a Hematololgy-Oncology Fellowship from 2005 to 2008.[17][11]

Career

[edit]

In 2008[18] Anders joined the School of Medicine of the University of North Carolina at Chapel Hill, where she worked with the UNC Lineberger Comprehensive Cancer Center.[3] In 2012, Anders helped to found the UNC Brain Metastases Specialty Clinic, becoming a co-director.[7][19] She has served as medical director of the UNC Breast Center and as an associate professor at UNC's School of Medicine in the Division of Hematology/Oncology.[20]

As of January 2019, Anders returned to the School of Medicine at Duke University Health System as a Translating Duke Health Scholar,[21][22] a professor of medicine, and the Medical Director for the Duke Center for Brain and Spine Metastasis (DCBSM).[21][23] In addition to being Medical Director, Anders served as Chief of the Division of Medical Oncology from 2021 to 2025.[24][5] In 2025, Anders was promoted from Co-Director of DCBSM to became the Director of DCBSM.[2]

Research

[edit]
External videos
video icon Carey K. Anders, MD, Duke Health Provider Profiles
video icon SABCS 2024: Brain Metastasis, San Antonio Breast Cancer Symposium, April 14, 2025

Anders studies the prognosis and treatment of brain metastasis from breast cancer.[3] She sequences genes from banked brain tumors to better understand the genetics of metastases related to different primary cancers.[4][25] She examines the effectiveness of treatments for patients with brain metastasis, a population that has been traditionally excluded from clinical trials. Anders' work has led to the development of novel therapies for those with brain metastases.[5][1][26]

Awards and honors

[edit]
  • 2011, Weatherspoon Family Brain Tumor Research Award[3][27]
  • 2011, Breast Cancer Research Foundation-AACR Grant for Translational Breast Cancer Research[28]
  • 2012, Clinical Investigator Award, Damon Runyon Cancer Research Foundation.[29][30][31][32]
  • 2016, Advanced Clinical Research Award (ACRA) in Breast Cancer, Conquer Cancer Foundation[25][7][33]
  • 2018-2019, Leadership Development Program, American Society of Clinical Oncology [34]
  • 2021, Clinical Cancer Advances, American Society of Clinical Oncology[9][10]
  • 2021, Women in Leadership Nominee, Women Leaders in Oncology[35]
  • 2023, Fellow, American Society of Clinical Oncology (FASCO).[8]
  • 2024, Chair's Commitment to Excellence Award, Duke University[36]

Selected publications

[edit]
  • Anders, CK; Hsu, DS; Broadwater, G; Acharya, CR; Foekens, JA; Zhang, Y; Wang, Y; Marcom, PK; Marks, JR; Febbo, PG; Nevins, JR; Potti, A; Blackwell, KL (10 July 2008). "Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression". Journal of Clinical Oncology. 26 (20): 3324–30. doi:10.1200/JCO.2007.14.2471. PMID 18612148.
  • Anders, CK; Johnson, R; Litton, J; Phillips, M; Bleyer, A (June 2009). "Breast cancer before age 40 years". Seminars in Oncology. 36 (3): 237–49. doi:10.1053/j.seminoncol.2009.03.001. PMC 2894028. PMID 19460581.
  • Anders, CK; Carey, LA (June 2009). "Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer". Clinical Breast Cancer. 9 Suppl 2 (Suppl 2): S73-81. doi:10.3816/CBC.2009.s.008. PMC 2919761. PMID 19596646.
  • Achrol, AS; Rennert, RC; Anders, C; Soffietti, R; Ahluwalia, MS; Nayak, L; Peters, S; Arvold, ND; Harsh, GR; Steeg, PS; Chang, SD (17 January 2019). "Brain metastases". Nature Reviews. Disease Primers. 5 (1): 5. doi:10.1038/s41572-018-0055-y. PMID 30655533.
  • Murthy, RK; Loi, S; Okines, A; Paplomata, E; Hamilton, E; Hurvitz, SA; Lin, NU; Borges, V; Abramson, V; Anders, C; Bedard, PL; Oliveira, M; Jakobsen, E; Bachelot, T; Shachar, SS; Müller, V; Braga, S; Duhoux, FP; Greil, R; Cameron, D; Carey, LA; Curigliano, G; Gelmon, K; Hortobagyi, G; Krop, I; Loibl, S; Pegram, M; Slamon, D; Palanca-Wessels, MC; Walker, L; Feng, W; Winer, EP (13 February 2020). "Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer". The New England Journal of Medicine. 382 (7): 597–609. doi:10.1056/NEJMoa1914609. hdl:20.500.11820/a1ba8d8f-77ae-4378-a1e1-e45533d2ee47. PMID 31825569.
  • Ramakrishna, Naren; Anders, Carey K.; Lin, Nancy U.; Morikawa, Aki; Temin, Sarah; Chandarlapaty, Sarat; Crews, Jennie R.; Davidson, Nancy E.; Franzoi, Maria Alice B.; Kirshner, Jeffrey J.; Krop, Ian E.; Patt, Debra A.; Perlmutter, Jane; Giordano, Sharon H. (10 August 2022). "Management of Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases: ASCO Guideline Update". Journal of Clinical Oncology. 40 (23): 2636–2655. doi:10.1200/JCO.22.00520. ISSN 0732-183X. PMID 35640075.[37][38][39][40]
  • Zimmer, AS; Van Swearingen, AED; Anders, CK (April 2022). "HER2-positive breast cancer brain metastasis: A new and exciting landscape". Cancer Reports. 5 (4): e1274. doi:10.1002/cnr2.1274. PMC 9124511. PMID 32881421.
  • Kaufman, PA; Neuberger, E; Schwartz, NRM; Wang, S; Liu, Y; Hsu, LI; Bartley, K; Blahna, MT; Pittner, BT; Wong, G; Anders, C (2023). "Real-world patient characteristics, treatment patterns, and clinical outcomes associated with tucatinib therapy in HER2-positive metastatic breast cancer". Frontiers in Oncology. 13 1264861. doi:10.3389/fonc.2023.1264861. PMC 10578436. PMID 37849811.

References

[edit]
  1. ^ a b c d Jablonski, Nicole (June 17, 2025). "Duke Center for Brain and Spine Metastasis Expands Treatment Options for Patients". Duke University Health System. Archived from the original on 26 June 2025. Retrieved 26 June 2025.
  2. ^ a b "New leadership announced for the Duke Center for Brain and Spine Metastasis". Duke Department of Neurosurgery. 9 April 2025. Retrieved 26 June 2025.
  3. ^ a b c d e Hughes, Tom (February 9, 2011). "Carey Anders, Katherine Hoadley are first recipients of new brain tumor research award". healthtalk.unchealthcare.org. Archived from the original on January 16, 2021. Retrieved December 10, 2020.
  4. ^ a b Hurvitz, Sara; McCann, Kelly (26 July 2018). HER2-Positive Breast Cancer. Elsevier Health Sciences. pp. 88–93. ISBN 978-0-323-58123-3.
  5. ^ a b c d Amorosi, Drew (October 26, 2023). "Novel therapies, technologies give 'hope for the future' to those with brain metastases". HemOnc Today. Archived from the original on 26 June 2025. Retrieved 26 June 2025.
  6. ^ Berberabe, Tony (22 October 2019). "Although Barriers to Treating Brain Metastases Exist, Systemic Therapies Make Progress". Oncology Nursing News. Retrieved 2 July 2025.
  7. ^ a b c Oleniacz, Laura (11 August 2016). "On the hunt for genetic clues to breast cancers that spread to the brain". UNC Lineberger.
  8. ^ a b "ASCO Congratulates 2023 Special Awards Recipients". ASCO Connection. March 29, 2023. Retrieved 26 June 2025.
  9. ^ a b "Work of 23 Conquer Cancer grant recipients featured among 2021 Clinical Cancer Advances | Conquer Cancer, the ASCO Foundation". www.conquer.org.
  10. ^ a b Smith, Sonali M.; Wachter, Kerri; Burris, Howard A.; Schilsky, Richard L.; George, Daniel J.; Peterson, Douglas E.; Johnson, Melissa L.; Markham, Merry Jennifer; Mileham, Kathryn F.; Beg, Muhammad S.; Bendell, Johanna C.; Dreicer, Robert; Keedy, Vicki L.; Kimple, Randall J.; Knoll, Miriam A.; LoConte, Noelle; MacKay, Helen; Meisel, Jane Lowe; Moynihan, Timothy J.; Mulrooney, Daniel A.; Mulvey, Therese Marie; Odenike, Olatoyosi; Pennell, Nathan A.; Reeder-Hayes, Katherine; Smith, Cardinale; Sullivan, Ryan J.; Uzzo, Robert (April 2021). "Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer". Journal of Clinical Oncology. 39 (10): 1165–1184. doi:10.1200/JCO.20.03420. ISSN 0732-183X. PMID 33527845.
  11. ^ a b "Carey Kernodle Anders | Duke University School of Medicine". medschool.duke.edu.
  12. ^ "Lucy Hendrick Kernodle, BSN'69" (PDF). Duke Nursing Magazine. Vol. 10, no. 2. 2014. p. 37. Retrieved 1 July 2025.
  13. ^ "Lucy Hendrick Kernodle, BSN'69" (PDF). Duke Nursing Alumni News. Vol. 1, no. 1. 2006. pp. 7–8. Retrieved 1 July 2025.
  14. ^ "DukeMed AlumniNews". Duke University. 2005. p. 28. hdl:2193/QB98MF46V.
  15. ^ "Elizabeth Hendrick Obituary (2007) - Rutherfordton, NC - Charlotte Observer". Legacy.com. Retrieved 1 July 2025.
  16. ^ "Class of 2002 | Brody Alumni Affairs | ECU". Brody School of Medicine, East Carolina University. Retrieved 1 July 2025.
  17. ^ "L I C E N S E E S E A R C H Licensee Information". North Carolina Medical Board. Retrieved 1 July 2025.
  18. ^ "Validating CYP2D6 Genotype-Guided Tamoxifen Therapy for a Multiracial U.S. Population". ClinicalTrials.gov. 2008-10-01.
  19. ^ McKee, MJ; Keith, K; Deal, AM; Garrett, AL; Wheless, AA; Green, RL; Benbow, JM; Dees, EC; Carey, LA; Ewend, MG; Anders, CK; Zagar, TM (January 2016). "A Multidisciplinary Breast Cancer Brain Metastases Clinic: The University of North Carolina Experience". The Oncologist. 21 (1): 16–20. doi:10.1634/theoncologist.2015-0328. PMC 4709216. PMID 26659221.
  20. ^ Oleniacz, Laura (13 February 2018). "Anders honored for delivering inaugural lecture". UNC Lineberger. Archived from the original on 29 June 2025. Retrieved 29 June 2025.
  21. ^ a b Harbin, Julie Poucher (25 August 2022). "White Glove Service for Brain and Spine Metastasis Patients". Duke University School of Medicine. Retrieved 30 June 2025.
  22. ^ Chew Minmin, S.; Bacotti, A.; Chen, Y.; Anders, C.; Sambade, M.; Deal, A. M.; Trembath, D.; McKee, M. J.; Brogi, E.; Seidman, A. D. (May 2023). "Impact of prior systemic therapy on lymphocytic infiltration in surgically resected breast cancer brain metastases". Breast Cancer Research and Treatment. 199 (1): 99–107. doi:10.1007/s10549-023-06908-0. ISSN 1573-7217. PMC 10865424. PMID 36930347.
  23. ^ "AACI Update" (PDF). News from the Association of American Cancer Institutes. February 2019.
  24. ^ "Diane Reidy-Lagunes will join Duke University School of Medicine as Chief of Division of Medical Oncology - OncoDaily". OncoDaily. 20 January 2025. Retrieved 29 June 2025.
  25. ^ a b "Conquer Cancer Foundation Awards $5.3 Million to Support Researchers Making Critical Strides in Clinical Cancer Research". ASCO Connection, American Society of Clinical Oncology.
  26. ^ Bath, Charlotte (October 25, 2020). "Clinical Challenges of Managing Breast Cancer Brain Metastases". The ASCO Post.
  27. ^ Starback, Peter (9 February 2011). "Anders, Hoadley are First Recipients of New Brain Tumor Research Award". UNC Lineberger. Retrieved 29 June 2025.
  28. ^ "UNC physician-scientist receives grant to study breast cancer brain metastases". EurekAlert!. March 25, 2011. Retrieved 29 June 2025.
  29. ^ Thorp, Holden (November 1, 2012). "SUCCESS STORY: Carey Anders, MD, and William Kim, MD, honored with Damon Runyon Cancer Research Foundation Clinical Investigator awards". University Cancer Research Fund Annual Report. University of North Carolina at Chapel Hill. p. 19. Retrieved 30 June 2025.
  30. ^ "Seed grant support leads to nationally-recognized research". 2011–2012 Donor Honor Rolls (PDF). UNC Lineberger Comprehensive Cancer Center. p. 5.
  31. ^ "Clinical Investigators: Current and Former Awardees". Damon Runyon.
  32. ^ "Carey K. Anders, MD". LBBC. July 26, 2019.
  33. ^ "ASCO Highlights: BCRF Supports the Future of Breast Cancer Research, Nurturing Young Scientists through CCF". Breast Cancer Research Foundation. 21 June 2016.
  34. ^ Oleniacz, Laura (15 June 2018). "Anders, Wang selected for American Society of Clinical Oncology Leadership Development Program". UNC Lineberger.
  35. ^ "8th Annual Women Leaders in Oncology Reception". Women Leaders in Oncology. June 7, 2021.
  36. ^ "Chair's Awards | Duke Department of Medicine". medicine.duke.edu. Archived from the original on 2025-06-29. Retrieved 2025-06-29.
  37. ^ Ramakrishna, Naren; Anders, Carey K.; Lin, Nancy U.; Morikawa, Aki; Temin, Sarah; Chandarlapaty, Sarat; Crews, Jennie R.; Davidson, Nancy E.; Franzoi, Maria Alice B.; Kirshner, Jeffrey J.; Krop, Ian E.; Patt, Debra A.; Perlmutter, Jane; Giordano, Sharon H. (10 August 2022). "Management of Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases: ASCO Guideline Update". Journal of Clinical Oncology. 40 (23): 2636–2655. doi:10.1200/JCO.22.00520. ISSN 0732-183X. PMID 35640075.
  38. ^ Harvey, Brittany (May 31, 2022). "Management of Advanced HER2-Positive Breast Cancer and Brain Metastases Guideline Update | Podcast | ASCO Publications". ascopubs.org. Retrieved 26 June 2025.
  39. ^ "Updated ASCO guidelines for patients with HER2-positive breast cancer". Cancer. 129 (1): 10. 2023. doi:10.1002/cncr.34588. ISSN 1097-0142. PMID 36507864.
  40. ^ "ASCO Guideline Update Supports New Second- and Third-line Systemic Treatments for HER2-Positive Breast Cancer". ASCO Daily News. June 2, 2022. Retrieved 26 June 2025.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Carey_K._Anders&oldid=1304770293"